Study: timing of deep brain stimulation matters for Parkinson's patients with GBA1 mutations
In 343 patients at 10 centers, GBA1 carriers who received DBS later in their disease declined faster cognitively than carriers treated earlier.
A study published on October 6 in Movement Disorders found that the timing of deep brain stimulation (DBS) affects cognitive outcomes in people with Parkinson’s disease who carry a GBA1 gene mutation. The international team, co-led by Gian Pal of Hackensack Meridian Neuroscience Institute, analyzed 343 patients from 10 centers in the United States and Europe. GBA1 carriers who had surgery later in the disease showed significantly faster cognitive decline than carriers treated earlier. Timing made no difference for people without the mutation. The authors point to roughly seven to eight years after diagnosis as the period when the choice matters most.
GBA1 variants are among the most common genetic risk factors for Parkinson’s, and earlier work had raised concerns about cognition after DBS in carriers. The result supports genetic testing as part of surgical planning. The study compared existing patient groups and was not a randomized trial.
Learn more: Deep brain stimulation